Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

SAN ANTONIO, and SAN FRANCISCO, Dec. 12, 2010 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with metastatic breast cancer during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).  NKTR-102, a novel investigational topoisomerase I inhibitor-polymer conjugate, is Nektar's lead oncology candidate and is being evaluated in multiple cancer indications.  The randomized Simon two-stage study presented at SABCS evaluated two 145 mg/m2 dose schedules of single-agent NKTR-102, every two weeks (q14d) and every three weeks (q21d), in 70 metastatic breast cancer patients who failed a prior taxane therapy.  Eighty-seven percent (61/70) of patients in the study received a prior anthracycline/taxane with or without capecitabine.

More than one million women worldwide are diagnosed with breast cancer every year and anywhere from 30% to 80% develop metastatic disease.(1)  

A total of 66 of the 70 patients treated in the Phase 2 study were assessable for the primary endpoint of objective tumor response rate (ORR),  including confirmed complete and partial responses per RECIST.  As of October 26, 2010, confirmed ORR for all evaluable patients was 32% (10/31) for the q14d schedule and 26% (9/35) for the q21d schedule, including two confirmed complete responses (CRs) on the q14d schedule.  An additional four patients had near CRs, with 100% disappearance of all target lesions.  The combined ORR for all evaluable patients was 29% (19/66).  Clinical benefit rate for the 66 evaluable patients was 41% (defined as CR+PR+SD greater than or equal to 6 mos).

"These are important new results for NKTR-102 in patients with metastatic breast cancer," said Prof. Ahmad Awada, Head of the Medical Oncology Clinic
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)...  Sutro Biopharma today announced that it has ... president of alliance and project management. Dr. Vasquez ... of Sutro,s collaborative partnerships and the development of ... antibodies and antibody-based therapeutics targeting immuno-oncology pathways. ... of experience in the biopharmaceutical sector with expertise ...
(Date:8/4/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a specialty ... an emphasis on the treatment of primary and metastatic ... studies in Europe and the ... Delivery System (CHEMOSAT) will be presented at the upcoming ... be held in Marseille, France , ...
(Date:8/4/2015)... , Aug. 4, 2015 BioElectronics ... over-the-counter ActiPatch® Musculoskeletal Pain Therapy medical devices, announced ... of its ActiPatch 7-day trial device has been ... Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More ... survey and submitted an assessment.  ...
Breaking Medicine Technology:Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2
... DIEGO, Oct. 7 The West Wireless Health ... to Alan Viars, of Videntity, at the Health ... and open source platforms to enable people to ... networks as they work towards achieving health and ...
... 7 VentiRx Pharmaceuticals, Inc., a biopharmaceutical company ... 8 (TLR8) candidates for the treatment of cancer, ... its randomized, placebo controlled clinical trial evaluating VTX-1463 ... demonstrated that VTX-1463 significantly improved allergy symptoms based ...
Cached Medicine Technology:West Wireless Health Institute Awards $10K Developer Challenge at Health 2.0 2West Wireless Health Institute Awards $10K Developer Challenge at Health 2.0 3VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis 2
(Date:8/4/2015)... ... ... Bayco Products, Inc. announces a new industrial-grade LED Dual-LightTM headlamp in a ... have a flip-up face shield. The sleek contours of the new Nightstick NSP-4614B ... their headlamp when raising or lowering their face shield or visor. The 4614 will ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... the United States, Richard Carmona, M.D., M.P.H., FACS, to its Board of Directors ... and will save lives," Dr. Carmona said. "I strongly believe in the mission ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... Food,” scheduled for Nov. 3 – 4, 2015, at UC San Diego, will ... new businesses, improve food access, and manage resources efficiently against the dueling backdrop ...
(Date:8/4/2015)... ... August 04, 2015 , ... Many men are confused about the safety of ... standing up as a voice of authority for men seeking accurate information about testosterone. ... special experience and expertise in the safe and effective treatment of low testosterone. In ...
(Date:8/4/2015)... ... 04, 2015 , ... They say a picture is worth a thousand words, ... medical art can be essential. StayWell, a health solutions company, announced today it will ... have been used by physicians and other health care providers for more than 40 ...
Breaking Medicine News(10 mins):Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3
... , TUESDAY, Oct. 25 (HealthDay News) -- Teens who don,t ... boys, in particular, may be at risk for obesity, new research ... female students at a Texas high school and found that the ... males and 6 hours 30 minutes for females. The average sleep ...
... USA - In a report on a preclinical investigation ... Anti-caries DNA Vaccine," lead author Wei Shi, Wuhan Institute ... of researchers demonstrate that anti-caries DNA vaccines, including pGJA-P/VAX, ... because of the low immunogenicity of DNA vaccines. This ...
... COLUMBIA, Mo. -- Parkway School District in Chesterfield, Mo., ... came to suicide prevention. With a minimal amount of ... next steps should be after a tragic incident had ... MU College of Education,s Missouri Partnership for Educational Renewal ...
... American women of childbearing age suffer from chronic pelvic ... to endometriosis, a puzzling condition where cells that normally ... begin to colonize other organs and tissues beyond ... laparoscopic surgeons explores endometriosis from both the patient,s and ...
... -- Men who drink plenty of low-sugar fluids may ... Although the reason for the association between ... theorize the fluids may flush out potential cancer-causing agents ... In conducting the study, Jiachen Zhou, a doctoral ...
... Atherosclerosis or buildup of fat in the walls ... older people but it affects a large number of young ... Foundation study. "The proportion of young, apparently healthy adults ... atherosclerosis is staggering," says Dr. Eric Larose, an interventional cardiologist ...
Cached Medicine News:Health News:Sleepy Teens More Prone to Weight Gain: Study 2Health News:IADR/AADR publish study on dental caries vaccine 2Health News:University of Missouri program helps teachers prevent teen suicides 2Health News:University of Missouri program helps teachers prevent teen suicides 3Health News:Close-up on endometriosis at 40th AAGL Global Congress 2Health News:Close-up on endometriosis at 40th AAGL Global Congress 3Health News:Close-up on endometriosis at 40th AAGL Global Congress 4Health News:Drinking More Fluids Could Lower Men's Bladder Cancer Risk 2Health News:Young, apparently healthy -- and at risk of heart disease 2Health News:Young, apparently healthy -- and at risk of heart disease 3
The RU is a low profile implantable bipolar tined permanent pacing lead for stimulation of either the atrium (J model) or the ventricle (straight model)....
The RZ is a small lead body profile implantable unipolar tined permanent pacing lead for stimulation of either the atrium (J model) or the ventricle (straight model)....
... The Vitatron Crystalline lead series ... designed for optimal sensing performance ... the sensing of far-field R ... leads allow a higher sensitivity ...
The Vitatron Excellence S+ lead series are endocardial leads providing excellent reliability and optimal pacing characteristics....
Medicine Products: